Influenza virus surface antigens: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
Influenza virus surface antigens: clinical details
Prescribing considerations
- Confirm that the product is appropriate for the current influenza season and patient group.
- Check previous influenza-vaccine reactions and allergy to active substances, excipients or manufacturing residues.
- Postpone during febrile illness or acute infection; minor illness without systemic upset is not generally a reason to defer.
- Assess thrombocytopenia, coagulation disorders and anticoagulant treatment before injection.
- Immune responses may be weaker during endogenous or treatment-related immunosuppression.
- Use separate sites when co-administering vaccines; do not mix products in the same syringe.
Contraindications and cautions
- Hypersensitivity to active substances, excipients or trace components including egg proteins, formaldehyde, cetyltrimethylammonium bromide, polysorbate 80 or gentamicin.
- Current febrile illness or acute infection requires postponement under the product licence.
Monitoring
- Ensure treatment and supervision for anaphylaxis are immediately available.
- Prevent injury from syncope or stress-related reactions around needle administration.
- Record the product name and batch number for traceability.
- Observe anticoagulated patients for injection-site bleeding or haematoma when relevant.
- Consider recent influenza vaccination when interpreting transient false-positive HIV, hepatitis C or HTLV-1 ELISA results.
Clinical pharmacology
An inactivated trivalent vaccine containing influenza haemagglutinin and neuraminidase surface antigens. It induces strain-directed humoral antibodies; pharmacokinetic assessment is not applicable.
Formulation and product differences
- The selected product is a non-live, non-adjuvanted, egg-cultured injectable vaccine supplied in a pre-filled syringe.
- It differs from live nasal, cell-cultured, recombinant, adjuvanted and high-dose influenza vaccines available for particular patient groups.
- Seasonal antigen composition changes, so verify that stock is intended for the current campaign.
Influenza virus surface antigens interactions
Important considerations involve immune response, concurrent vaccination and injection-site bleeding.
Immunosuppressants, including systemic corticosteroids and cytotoxic medicines
They may reduce the immune response, although the inactivated vaccine can still be administered when clinically appropriate.
Other vaccines
They may be given at the same appointment using separate sites, but adverse effects may be more noticeable.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.